Increased gene expression of collagen Types I and III is inhibited by β-receptor blockade in patients with dilated cardiomyopathy

European Heart Journal

Volumn 26, Issue 24, 2005, Pages 2698-2705

  Shigeyama, Junsho ^a   Yasumura, Yoshio ^a   Sakamoto, Aiji ^a   Ishida, Yoshio ^a   Fukutomi, Tatsuya ^b   Itoh, Makoto ^b   Miyatake, Kunio ^a   Kitakaze, Masafumi ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Blocker; Collagen synthesis; Dilated cardiomyopathy; Heart failure; Myocardial gene expression

Indexed keywords

(3 IODOBENZYL)GUANIDINE; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; COLLAGEN TYPE 1; COLLAGEN TYPE 3; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; ARTICLE; CLINICAL ARTICLE; COLLAGEN SYNTHESIS; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; HEART INNERVATION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE BIOPSY; HEART PROTECTION; HEART RIGHT VENTRICLE; HUMAN; MALE; PRIORITY JOURNAL; RECEPTOR BLOCKING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYMPATHETIC INNERVATION; SYMPATHETIC NERVE;

ADRENERGIC BETA-ANTAGONISTS; CARDIOMYOPATHY, DILATED; COLLAGEN TYPE I; COLLAGEN TYPE III; DNA, COMPLEMENTARY; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOBLOTTING; MALE; MIDDLE AGED; PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 28544443526     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehi492     Document Type: Article

References (38)

1. Eicchorn EJ, Bristow MR. Medical therapy can improve the biological properties of the chronically failing heart. A new era I the treatment of heart failure. Circulation 1996;94:2285-2296.
2. Lowes BD, Gilbert EM, Abraham WT, Minobe WA, Larrabee P, Ferguson D, Wolfel EE, Lindenfeld J, Tsvetkova T, Robertson AD, Quaife RA, Bristow MR. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N Engl J Med 2002;346:1357-1365.
3. Yasumura Y, Takemura K, Sakamoto A, Kitakaze M, Miyatake K. Changes in myocardial gene expression associated with β-blocker therapy in patients with chronic heart failure. J Cardiac Fail 2003;9:469-474.
4. Weber KT. Cardiac interstium in health and disease: the fibrillar collagen network. J Am Coll Cardiol 1989;13:1637-1652.
5. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol 2000;35:569-582.
6. Manabe I, Shindo T, Nagai R. Gene expression in fibroblasts and fibrosis. Involvement in cardiac hypertrophy. Circ Res 2002;91:1103-1113.
7. Pauschinger M, Knopf D, Petschauer S, Doerner A, Poller W, Schwimmbeck PL, Kuhl U, Schultheiss HP. Dilated cardiomyopathy is associated with significant changes in collagen type I/III ratio. Circulation 1999; 99:2750-2756.
8. Villarreal FJ, Dillmann WH. Cardiac hypertrophy-induced changes in mRNA levels for TGF-beta 1, fibronectine and collagen. Am J Physiol 1992;262:H1861-H1866.
9. Fielitz J, Hein S, Mitrovic V, Pregla R, Zurbrugg HR, Warnecke C, Schaper J, Fleck E, Regitz-Zagrosek V. Activation of the cardiac renin-angiotensin system and increased myocardial collagen expression in human aortic valve disease. J Am Coll Cardiol 2001;37:1443-1449.
10. Taniyama Y, Morishita R, Nakagami H, Moriguchi A, Sakonjo H, Shokei-Kim, Matsumoto K, Nakamura T, Higaki J, Ogihara T. Potential contribution of a novel antifibrotic factor, hepatocyte growth factor, to prevention of myocardial fibrosis by angiotensin II blockade in cardiomyopathic hamsters. Circulation 2000;102:246-252.
11. Masson S, Arosio B, Luvara G, Gagliano N, Fiordaliso F, Santambrogio D, Vergani C, Latini R, Annoni G. Remodeling of cardiac extracellular matrix during β-adrenergic stimulation: upregulation of SPARC in the myocardium of adult rats. J Moll Cell Cardiol 1998;30:1505-1514.
12. Barth W, Deten A, Bauer M, Reinohs M, Leicht M, Zimmer HG. Differential remodeling of the left and right heart after norepinephrine treatment in rats: studies on cytokines and collagen. J Moll Cell Cardiol 2000;32:273-284.
13. Bhambi B, Eghbali M. Effect of norepinephrine on myocardial collagen gene expression and response of cardiac fibroblasts after norepinephrine treatment. Am J Pathol 1991;139:1131-1142.
14. Latini R, Masson S, Jeremic G, Luvara G, Fiordaliso F, Calvillo L, Bernasconi R, Torri M, Rondelli I, Razzetti R, Bongrani S. Comparative efficacy of a DA2/α2 agonist and a β-blocker in reducing adrenergic drive and cardiac fibrosis I an experimental model of left ventricular dysfunction after coronary artery occlusion. J Cardiovasc Pharmacol 1998;31:601-608.
15. Grimm D, Huber M, Jabusch HC, Shakibaei M, Fredersdorf S, Paul M, Riegger GA, Kromer EP. Extracellular matrix proteins in cardiac fibroblasts derived from rat hearts with chronic pressure overload: effects of beta-receptor blockade. J Moll Cell Cardiol 2001;33:487-501.
16. Imamura Y, Ando H, Ashihara T, Fukuyama T. Myocardial adrenergic nervous activity is intensified in patients with heart failure without left ventricular volume or pressure overload. J Am Coll Cardiol 1996;28:371-375.
17. Dae MW, De Marco T, Botvinick EH, O'Connell JW, Hattner RS, Huberty JP, Yuen-Green MS. Scintigraphic assessment of MIBG uptake in globally denervated human and canine hearts-implications for clinical studies. J Nucl Med 1992;33:1444-1450.
18. Matsui T, Tsutamoto T, Kinoshita M. Relationship between cardiac 1231-metaiodobenzylguanidine imaging and the transcardiac gradient of neurohumoral factors in patients with dilated cardiomyopathy. Circ J 2001;65:1041-1046.
19. Fielitz J, Hein S, Mitrovic V, Pregla R, Zurbrugg HR, Warnecke C, Schaper J, Fleck E, Regitz-Zagrosek V. Activation of the cardiac renin-angiotensin system and increased myocardial collagen expression in human aortic valve disease. J Am Coll Cardiol 2001;37:1443-1449.
20. Studer R, Reinecke H, Muller B, Holtz J, Just H, Drexler H. Increased angiotensin-I converting enzyme gene expression in the failing human heart. Quantification by competitive RNA polymerase chain reaction. J Clin Invest 1994;94:301-310.
21. Regitz-Zagrosek V, Fielitz J, Dreysse R, Hildebrandt AG, Fleck E. Angiotensin receptor type 1 mRNA in human right ventricular endomyocardial biopsies: downregulation in heart failure. Cardiovasc Res 1997;35:99-105.
22. Bishop JE, Greenbaum R, Gibson DG, Yacoub M, Laurent GJ. Enhanced deposition of predominantly type I collagen in myocardial disease. J Moll Cell Cardiol 1990;22:1157-1165.
23. Marijianowski MM, Teeling P, Mann J, Becker AE. Dilated cardiomyopathy is associated with increase in the type I/type III collagen ratio: a quantitative assessment. J Am Coll Cardiol 1995;25:1263-1272.
24. Yoshikane H, Honda M, Goto Y, Morioka S, Ooshima A, Moriyama K. Collagen in dilated cardiomyopathy: scanning electron microscopic and immunohistochemical observations. Jpn Circ J 1992;56:899-910.
25. Barth M, Deten A, Bauer M, Reinohs M, Leicht M, Zimmer HG. Differential remodeling of the left and right heart after norepinephrine treatment in rats: studies on cytokines and collagen. J Moll Cell Cardiol 2000;32:273-284.
26. Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, Heine UI, Liotta LA, Falanga V, Kehrl JH, Fauci AS. Transforming growth factor type β: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 1986;83:4167-4171.
27. Eghbali M, Tomek R, Sukhatme VP, Woods C, Bhambi B. Differential effects of transforming growth factor type β1 and phorbol myristate acetate on cardiac fibroblasts: regulation of fibrillar collagen mRNA and expression of early transcription factors. Circ Res 1991;69:483-490.
28. Eichhorn EJ, Bristow M. Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure. Circulation 1996;84:2285-2296.
29. Weber KT, Pick R, Jalil JE, Janicki JS, Carroll EP. Patterns of myocardial fibrosis. J Moll Cell Cardiol 1989;21(Suppl. 5):121-131.
30. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure: US Carvedilol Heart Failure Study Group. N Engl J Med 1996;334:1349-1355.
31. Packer M, Colucci WS, Sackner-Bernstein JD, Liang CS, Goldscher DA, Freeman I, Kukin ML, Kinhal V, Udelson JE, Klapholz M, Gottlieb SS, Pearle D, Cody RJ, Gregory JJ, Kantrowitz NE, LeJemtel TH, Young ST, Lukas MA, Shusterman NH. Double blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure: the PRECISE Trial: Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. Circulation 1996;94:2793-2799.
32. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL; Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-1658.
33. CIBIS II Investigators and Committees. The cardiac Insufficiency Bisoprolol Study II (CIBIS II): a randomized trial. Lancet 1999;353:9-13.
34. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996;94:2807-2816.
35. Hori M, Sasayama S, Kitabatake A, Toyo-oka T, Handa S, Yokoyama M, Matsuzaki M, Takeshita A, Origasa H, Matsui K, Hosoda S; MUCHA Investigators. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: The Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. Am Heart J 2004;147:324-330.
36. Graven KK, McDonald RJ, Farber HW. Hypoxic regulation of endothelial glyceraldehyde-3-phosphate dehydrogenase. Am J Physiol 1998;274:C347-C355.
37. Engelhardt S, Bohm M, Erdmann E, Lohse MJ. Analysis of beta-adrenergic receptor mRNA levels in human ventricular biopsy specimens by quantitative polymerase chain reactions: progressive reduction of beta1-adrenergic receptor mRNA in heart failure. J Am Coli Cardiol 1996;27:146-154.
38. Moniotte S, Vaerman JL, Kockx MM, Larrouy D, Langin D, Noirhomme P, Balligand JL. Real-time RT-PCR for the detection of beta-adrenoceptor messenger RNAs in small human endomyocardial biopsies. J Mol Cell Cardiol 2001;33:2121-2133.